Image Trademark with Serial Number 79108413
Status: 709 - Registration cancelled because registrant did not file an acceptable declaration under Section 71
Serial Number
79108413
Registration Number
4311029
Word Mark
Status
709 - Registration cancelled because registrant did not file an acceptable declaration under Section 71
Status Date
2019-11-08
Filing Date
2012-01-03
Registration Number
4311029
Registration Date
2013-04-02
Mark Drawing
2000 - Illustration: Drawing or design without any word(s)/letter(s)/ number(s)
Typeset
Design Searches
260103, 261701, 261704, 261709 - Incomplete circles (more than semi-circles). Straight line(s), band(s) or bar(s). Vertical line(s), band(s) or bar(s). Curved line(s), band(s) or bar(s).
Published for Opposition Date
2013-01-15
Law Office Assigned Location Code
L60
Employee Name
MIDDLETON, BERNICE L
Statements
Indication of Colors claimed
Color is not claimed as a feature of the mark.
Description of Mark
The mark consists of an abstract incomplete circle.
Goods and Services
Medicines for human purpose, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Pharmaceutical preparations, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Chemico-pharmaceutical preparations, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; Capsules for pharmaceutical purposes, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; Raw material drug, namely, active pharmaceutical ingredients which are used for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system,digestive system and endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases; Chinese medicine nostrum, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Biochemical medicines, for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system, for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Dietetic substances adapted for medical use, beverages or food which are used for treating diseases of cardiovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system and immune system for treating hypersensitivity diseases and for treating musculo-skeletal disorders; Additives to fodder for medical use; Medicines for veterinary purposes, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system,digestive system and endocrine system, for the treatment of infective diseases,for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for treating hypersensitivity diseases for use in veterinary
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
F - Section 71 - Cancelled
Class Status Date
2019-11-08
Primary Code
005
Correspondences
Name
ADVANCE CHINA IP LAW OFFICE
Address
Please log in with your Justia account to see this address.
International Registrations
International Registration Number
1104918
International Registration Date
2012-01-03
International Publication Date
2012-02-16
International Renewal Date
2022-01-03
Auto Protection Date
2021-01-04
International Status
001 - Request for extension of protection established
International Status Date
2012-02-09
Priority Claimed In
False
First Refusal In
True
Trademark Events
Event Date | Event Description |
2012-02-09 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
2012-02-10 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2012-02-14 | APPLICATION FILING RECEIPT MAILED |
2012-04-06 | ASSIGNED TO EXAMINER |
2012-06-07 | NON-FINAL ACTION WRITTEN |
2012-06-08 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
2012-06-08 | REFUSAL PROCESSED BY MPU |
2012-06-08 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
2012-07-01 | REFUSAL PROCESSED BY IB |
2012-10-30 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2012-10-30 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2012-10-31 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2012-11-26 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2012-12-10 | ASSIGNED TO LIE |
2012-12-10 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
2012-12-26 | NOTICE OF PUBLICATION |
2012-12-26 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
2012-12-26 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
2013-01-15 | PUBLISHED FOR OPPOSITION |
2013-02-20 | NOTIFICATION PROCESSED BY IB |
2013-04-02 | REGISTERED-PRINCIPAL REGISTER |
2013-07-02 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
2013-07-03 | FINAL DISPOSITION PROCESSED |
2013-07-03 | FINAL DISPOSITION NOTICE SENT TO IB |
2013-07-20 | FINAL DECISION TRANSACTION PROCESSED BY IB |
2014-08-07 | NEW REPRESENTATIVE AT IB RECEIVED |
2018-12-07 | NEW REPRESENTATIVE AT IB RECEIVED |
2019-07-04 | NEW REPRESENTATIVE AT IB RECEIVED |
2019-07-05 | CORRECTION TRANSACTION RECEIVED FROM IB |
2019-10-08 | CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED |
2019-11-08 | CANCELLED SECTION 71 |
2020-07-08 | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED |
2020-08-15 | GENERIC MADRID TRANSACTION CREATED |
2020-08-16 | GENERIC MADRID TRANSACTION SENT TO IB |
2020-09-12 | TOTAL INVALIDATION PROCESSED BY THE IB |